Hepion Pharmaceuticals, Inc.
HEPA
|
News
|
$2.11
-0.09%
-0.09%
73K
|
Health Technology
(0.0% 1d) (-13.4% 1m) (-86.0% 1y) (-4.7% 2d) (-5.6% 3d) (-7.8% 7d) (424.83% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 11,546,872
http://www.hepionpharma.com
Sec Filling | Patents | 12 employees
(US) Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
liver liver disease treatment
add to watch list Paper trade email alert is off
Press-releases
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
Published: 2024-04-19 (Crawled : 20:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
| Email alert
Add to watchlist
pharmaceuticals trial
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
Published: 2024-03-06 (Crawled : 13:30) - globenewswire.com
EXPR | $0.77 0.0% 7.7K
|
Retail Trade
|
| O: 4.04%
H: 2.59%
C: -1.29%
IMXI | $21.34 -0.05% -0.05% 120K
|
Finance
|
| O: 2.51%
H: 2.35%
C: 0.83%
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -1.15%
H: 4.28%
C: -10.89%
pharmaceuticals
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
Published: 2024-02-16 (Crawled : 13:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -15.19%
H: 52.4%
C: 11.79%
million pharmaceuticals
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Hepion Pharmaceuticals to Present at NASH-TAG 2024
Published: 2024-01-03 (Crawled : 22:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 0.0%
H: 1.29%
C: -4.67%
pharmaceuticals
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Published: 2023-12-07 (Crawled : 13:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -1.85%
H: 3.46%
C: -3.77%
management pharmaceuticals
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 0.33%
H: 2.25%
C: -1.77%
obesity drug pharmaceuticals nash
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -17.36%
H: 16.86%
C: 2.46%
liver disease treatment pharmaceuticals study
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Published: 2023-11-10 (Crawled : 14:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 2.05%
H: 29.77%
C: 1.34%
liver conference review pharmaceuticals trial phase 2
Stock futures slip after Nasdaq registers 7-day win streak: Live updates – CNBC
Published: 2023-11-07 (Crawled : 04:00) - spacfeed.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: -0.52%
H: 2.86%
C: -6.25%
nasdaq
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10